Faget Quoted in MedTech Dive on the FDA’s Response to the COVID Crisis
March 15, 2021
MedTech Dive
Kyle Faget, partner and member of the firm’s Health Care and Life Sciences Industry Team, was quoted in a MedTech Dive article titled, “5 Things Medtech Can Expect from FDA in 2021.”
Faget told MedTech Dive that she sees the FDA in 2021 releasing its long-awaited publication of the revised Quality System Regulation. She also stated that: “What we saw a lot of in the Trump administration was HHS getting very involved in FDA’s business and we’re going to see less of that.” She continued, “There’s going to be much more deference to FDA as an independent regulatory body.”
Related News
October 9, 2026
In the News
Jonathan Lasken Highlighted Across the Media for Arrival to Foley
Foley & Lardner LLP partner Jonathan Lasken is highlighted across the media for his recent arrival to the firm’s Washington D.C. office.
October 7, 2026
In the News
William Holtz Examines New FDA Approach to Clinical Trial Development
Foley & Lardner LLP of counsel William Holtz is quoted in the PharmaVoice article, “5 Key Facts About the FDA Expedited IND Pilot Program,” examining the FDA's new pilot program and its potential to accelerate clinical research.
October 5, 2026
In the News
Louis Lehot Analyzes U.S. IPO Market Trends and Outlook
Foley & Lardner LLP partner Louis Lehot is featured in the Daily Journal‘s Capital & Counsel newsletter offering insights on the current state of the U.S. IPO market and the factors influencing companies' routes to going public.